Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFIL2-REP low-dose interleukin-2 in recent-onset type 1 diabetes
2024-514043-29-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing ciclosporin + ILT-101 with ciclosporin + placebo of ILT-101 (2 arms). Planned start Jul 2024; status: authorised.
02
Drugs
aldesleukin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2024-514043-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514043-29-00.